Allogeneic platelet-rich plasma is produced by using the blood from unknown blood donors. Platelet-rich plasma is a concentrated form of blood plasma that contains higher number of platelets than the normal blood plasma. Ideally, platelet-rich plasma contains five to ten times more platelets than the normal blood plasma. Increasing number of injuries caused by accidents is a key driver for the global platelet-rich plasma market. Rapidly increasing prevalence of orthopedic injuries and rising number of sports injuries are likely to boost the global allogeneic platelet-rich plasma market during the forecast period. The count of the growth factors is high, and is more effective as compared to autologous platelet-rich plasma, these factors are the driving the global allogeneic platelet-rich plasma market. The wound healing time is short and the concentration of growth factors is high are some of the advantages over the other platelet-rich plasma derivatives. These are some of the factors likely to propel the global allogeneic platelet-rich plasma market from 2017 to 2025.
Read Report Overview: https://www.transparencymarketresearch.com/allogeneic-plateletrich-plasma-market.html
Allogeneic platelet-rich plasma shows significant clinical effectiveness in patients with chronic disorders. This factor is estimated to drive the market during the forecast period. For instance, the level of platelets and growth factors is low in patients suffering from communicable or vector-borne diseases such as dengue, malaria, and hepatitis, which is insufficient to show any significant clinical action. In such cases, platelet-rich plasma derived from the allogeneic blood sample is preferred. This fuels the market for allogeneic platelet-rich plasma. However, the threat of transfer of chronic diseases such as syphilis, hepatitis, and other blood-borne diseases in case of allogeneic platelet-rich plasma is likely to restrict the market during the forecast period. Although this threat is self-limiting (due to strict norms regarding blood screening), it is considered a barrier (albeit not strong enough) for the market. Thus, the threat of therapy failure is likely to hamper the market from 2017 to 2025. The global allogeneic platelet-rich plasma market can be segmented based on application, type, and region. Based on application, the market can be categorized into orthopedic surgery, neurosurgery, cosmetic surgery, general surgery, and others. In terms of type, the market can be divided into allogeneic leukocyte-rich platelet-rich plasma, allogeneic pure platelet-rich plasma, and allogeneic pure platelet-rich fibrin / leukocyte-rich platelet-rich fibrin.
Geographically, the global allogeneic platelet-rich plasma market can be divided into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America held the leading market share in 2016, due to technological advancements and increasing awareness about allogeneic platelet-rich plasma therapy in the region. Europe held the second-largest market share in 2016, due to higher number of growth factors present in allogeneic platelet-rich plasma compared to autologous platelet-rich plasma.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36023
The expected positive outcome of these studies may promote growth of the allogeneic platelet-rich plasma market during the forecast period. The market in Asia Pacific is anticipated to expand from 2017 to 2015, due to higher number of growth factors present in allogeneic platelet-rich plasma products compared to autologous platelet-rich plasma products and certain clinical studies proving the efficacy of allogeneic platelet-rich plasma in new applications.
Key players operating in the global allogeneic platelet-rich plasma market include Arthrex, Inc., Zimmer Biomet, Cesca Therapeutics, Inc., DePuy Synthes (Johnson & Johnson), and Stryker Corporation.